You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖(02696.HK):HLX10聯合白蛋白紫杉醇治療一線化療失敗的晚期宮頸癌(CC)2期臨牀完成首例患者給藥
格隆匯 03-11 21:04

格隆匯3月11日丨復宏漢霖-B(02696.HK)公告,近日,公司重組抗PD-1人源化單克隆抗體注射液(HLX10)聯合白蛋白紫杉醇治療一線化療失敗的晚期宮頸癌(CC)的2期臨牀研究於中國境內完成首例患者給藥。

該研究為一項單臂、開放、多中心的2期臨牀研究,主要目的為評估HLX10聯合白蛋白紫杉醇治療一線化療失敗的晚期宮頸癌患者的臨牀療效,其次旨在評估HLX10聯合白蛋白紫杉醇在該患者羣體中的安全性和耐受性,以及生物標誌物(PD-L1,MSI1和TMB2)和療效的相關性。實驗還將開展羣體藥代動力學和藥效動力學的分析。

該候選藥物為公司自主研發的創新型治療用生物製品,擬用於實體瘤治療,目前正進一步探索用於治療慢性B型肝炎(即慢性乙型肝炎)的可能性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account